Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia

Sílvia Casas, Bálint Nagy, Erkki Elonen, Anna Aventín, Marcelo L. Larramendy, Jorge Sierra, Tapani Ruutu, Sakari Knuutila

Research output: Contribution to journalArticle

47 Citations (Scopus)


Previous gene function analyses have indicated that HOXA9, DEK, CBL and CSF1R are aberrantly expressed in acute myeloid leukemia (AML). We analyzed the expression of these genes in a series of 41 adult patients with AML using quantitative real-time RT-PCR, and tested the association of the expression with the following hematologic and clinical parameters: age, FAB, immunophenotype and karyotype aberrations. A high proportion of the patients showed over- or underexpression of the analyzed genes. DEK was overexpressed in 98% of the cases, whereas CBL, CSF1R and HOXA9 were either overexpressed in 20%, 17% and 78% or underexpressed in 20%, 42% and 15% of the cases, respectively. Patients whose karyotype contained t(8;21)(q22;q22), showed lower relative expression of HOXA9 at a statistically significant level (p < 0.05). Bone marrow samples without expression of CD34 antigen were associated with either overexpression of DEK or HOXA9. Furthermore, an association was found between the AML-M2 subtype and lower expression of CBL, CSF1R or HOXA9, and between the AML-M5 subtype and CBL or CSF1R overexpression.

Original languageEnglish
Pages (from-to)1935-1941
Number of pages7
JournalLeukemia and Lymphoma
Issue number11
Publication statusPublished - Nov 1 2003



  • Acute myeloid leukemia
  • Array-based methods
  • Gene expression
  • Quantitative real-time RT-PCR

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Casas, S., Nagy, B., Elonen, E., Aventín, A., Larramendy, M. L., Sierra, J., Ruutu, T., & Knuutila, S. (2003). Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leukemia and Lymphoma, 44(11), 1935-1941. https://doi.org/10.1080/1042819031000119299